Immunotherapy combination extends survival in advanced endometrial cancer

The global phase 3 DUO-E trial showed that durvalumab plus chemotherapy followed by maintenance with durvalumab and olaparib achieved a median overall survival of 51.1 months in patients with advanced or recurrent endometrial cancer, 11.5 months longer than the chemotherapy arm. The trial randomized 718 patients; at 36 months, survival was 63.4% in the combination arm versus 52% with chemotherapy, and the current analysis observed no new safety concerns. Results were presented at the ESMO Congress 2026, and the final overall survival analysis is ongoing.